• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

    3/12/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email

    — Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project —

    — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple Clinical Settings —

    — Application Period to Run From March 16, 2026 Through June 1, 2026 —

    Alkermes plc (NASDAQ:ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or community health center settings and who possess a commitment to advancing treatment of schizophrenia or bipolar I disorder. The application period will run through June 1, 2026.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310230842/en/

    "Psychiatric-mental health nurse practitioners bring deep, real‑world insight from the front lines of care," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes. "Over the last eight years, Alkermes has demonstrated a strong commitment to supporting early‑career investigators through the Alkermes Pathways Research Awards® program, helping to foster innovative research at pivotal stages in scientific careers. The launch of the Alkermes Pathways APN Research Awards program represents an important evolution of that commitment – expanding our support to advanced practice nurses whose unique perspectives can further inform clinical practice and deepen understanding of serious mental illness, including schizophrenia and bipolar I disorder. We are especially proud to launch this innovative program ahead of this spring's International Society of Psychiatric Mental Health Nurses and Psych Congress Nurse Practitioner Institute annual meetings."

    "This program creates a meaningful opportunity for nurse practitioners to advance research questions grounded in clinical reality," said Professor Cynthia Handrup, DNP, Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Illinois Chicago and chair of the Alkermes Pathways APN Research Awards review committee. "I'm honored to work with Alkermes and the review committee to help identify projects with the potential to strengthen evidence and improve patient care."

    The inaugural Alkermes Pathways APN Research Awards program will offer grants in amounts up to $10,000 per project. To qualify, psychiatric-mental health nurse practitioners must be engaged in clinical, academic and/or community health settings and possess a doctoral degree (Ph.D, DNP, etc.) or have a co-investigator or mentor who does. Applications will be formally reviewed by an independent review committee comprised of prominent researchers in the relevant field. For more information on the Alkermes Pathways APN Research Awards program, including full eligibility criteria and how to apply for the inaugural edition of the program, visit http://www.alkermes.com/pathways-apn.

    About Alkermes plc

    Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson's disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

    Alkermes Pathways APN Research Awards™ is a registered service mark of Alkermes, Inc.

    Alkermes Pathways Research Awards® is a registered service mark of Alkermes, Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260310230842/en/

    Alkermes Contacts:

    For Investors: Sandy Coombs, +1 781 609 6377

    For Media: Gretchen Murphy, +1 781 609 6419

    Get the next $ALKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    2/24/2026$45.00Outperform
    Wolfe Research
    11/11/2025$50.00Buy
    Truist
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Alkermes Plc with a new price target

    Wolfe Research initiated coverage of Alkermes Plc with a rating of Outperform and set a new price target of $45.00

    2/24/26 7:45:07 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Alkermes Plc with a new price target

    Truist initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $50.00

    11/11/25 8:03:02 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    SEC Form 10-K filed by Alkermes plc

    10-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 9:31:15 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    2/25/26 7:05:28 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

    — Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple Clinical Settings — — Application Period to Run From March 16, 2026 Through June 1, 2026 — Alkermes plc (NASDAQ:ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or

    3/12/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Present at the Stifel 2026 Virtual CNS Forum

    Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET (12:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes' pipeline includes

    3/10/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988

    2/25/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, Chief Financial Officer Reed Joshua

    4 - Alkermes plc. (0001520262) (Issuer)

    3/4/26 8:21:27 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director and CEO, Alkermes plc Pops Richard F

    4 - Alkermes plc. (0001520262) (Issuer)

    3/4/26 8:20:22 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Finance (Interim PAO) Parisi Samuel Joseph sold $201,808 worth of Ordinary Shares (6,890 units at $29.29), decreasing direct ownership by 47% to 7,717 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    3/4/26 8:19:23 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

    Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results and expectations and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988

    2/25/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

    Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company's fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visit

    2/11/26 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca

    11/19/25 6:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes plc Announces CEO Succession Plan

    — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes' Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors — Alkermes plc (NASDAQ:ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes' Board of Directors (the Board) appointed Blair Jackson, Alkermes' current Executive Vice President, Chief Operating Officer, as the company's next CEO, effective Aug. 1,

    2/25/26 6:55:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care